Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report
- Authors:
- Maria Celeste Palmarocchi
- Ruben Carlo Balzarotti Canger
- Piercarlo Saletti
-
Affiliations: Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland, Department of Surgery, Lugano Regional Hospital, 6900 Lugano, Switzerland - Published online on: April 11, 2017 https://doi.org/10.3892/ol.2017.6026
- Pages: 4445-4452
This article is mentioned in:
Abstract
Siegel R, Ma JM, Zou ZH and Jemal A: Cancer statistics, 2014. Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar | |
Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI | |
American Joint Committee on Cancer (AJCC), . TNM staging system. September 6–2013, American Cancer Society; | |
Tamm EP, Silverman PM, Charnsangavej C and Evans DB: Diagnosis, staging, and surveillance of pancreatic cancer. AJR Am J Roentgenol. 180:1311–1323. 2003. View Article : Google Scholar : PubMed/NCBI | |
Varadachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB and Wolff RA: Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol. 13:1035–1046. 2006. View Article : Google Scholar : PubMed/NCBI | |
Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, et al: Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 20:2787–2795. 2013. View Article : Google Scholar : PubMed/NCBI | |
Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ and Pisters PW: Combined modality treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement. Ann Surg Oncol. 16:1751–1756. 2009. View Article : Google Scholar : PubMed/NCBI | |
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI | |
von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI | |
Tempero MA, Malafa MP, Behrman, Benson AB III, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, et al: Pancreatic adenocarcinoma, version 2.2014: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 12:1083–1093. 2014. View Article : Google Scholar : PubMed/NCBI | |
Valls C, Andía E, Sanchez A, Fabregat J, Pozuelo O, Quintero JC, Serrano T, Garcia-Borobia F and Jorba R: Dual-phase helical CT of pancreatic adenocarcinoma: Assessment of resectability before surgery. AJR Am J Roentgenol. 178:821–826. 2002. View Article : Google Scholar : PubMed/NCBI | |
Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, Coste J, Louvel A, Roseau G, Couturier D and Bonnin A: Pancreatic tumors: Comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol. 170:1315–1322. 1998. View Article : Google Scholar : PubMed/NCBI | |
DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, Ciaccia D, Lane KA, Maglinte D, Kopecky K, et al: Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med. 141:753–763. 2004. View Article : Google Scholar : PubMed/NCBI | |
Michl P, Pauls S and Gress TM: Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol. 20:227–251. 2006. View Article : Google Scholar : PubMed/NCBI | |
Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B and Mahipal A: PET/CT fusion scan prevents futile laparotomy in early stage pancreatic cancer. Clin Nucl Med. 40:e501–e505. 2015. View Article : Google Scholar : PubMed/NCBI | |
Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, et al: Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 118:5749–5756. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, et al: Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 261:12–17. 2015. View Article : Google Scholar : PubMed/NCBI | |
Hsu CC, Wolfgang CL, Laheru DA, Pawlik TM, Swartz MJ, Winter JM, Robinson R, Edil BH, Narang AK, Choti MA, et al: Early mortality risk score: Identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg. 16:753–761. 2012. View Article : Google Scholar : PubMed/NCBI | |
Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, et al: Serum carbohydrate antigen 19–9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 16:430–438. 2014. View Article : Google Scholar : PubMed/NCBI | |
Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, et al: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 27:1806–1813. 2009. View Article : Google Scholar : PubMed/NCBI | |
Singh P, Wig JD, Srinivasan R and Radotra BD: A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma. Indian J Cancer. 48:170–174. 2011. View Article : Google Scholar : PubMed/NCBI | |
Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C and Goggins M: Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 25:319–325. 2007. View Article : Google Scholar : PubMed/NCBI | |
Miyoshi K, Sato N, Ohuchida K, Mizumoto K and Tanaka M: SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. Anticancer Res. 30:867–871. 2010.PubMed/NCBI | |
Prenzel KL, Warnecke-Eberz U, Xi H, Brabender J, Baldus SE, Bollschweiler E, Gutschow CA, Hölscher AH and Schneider PM: Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncol Rep. 15:1397–1401. 2006.PubMed/NCBI | |
Nagaraju GP, Dontula R, El-Rayes BF and Lakka SS: Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. Carcinogenesis. 35:967–973. 2014. View Article : Google Scholar : PubMed/NCBI | |
Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P and Gradishar WJ: Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs. 19:899–909. 2008. View Article : Google Scholar : PubMed/NCBI | |
Xiong HQ and Abbruzzese JL: Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 29 5 Suppl 14:S31–S37. 2002. View Article : Google Scholar | |
Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG and Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 13:565–569. 1993.PubMed/NCBI | |
Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA and Ahrendt SA: Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res. 9:4165–4171. 2003.PubMed/NCBI | |
van der Zee JA, van Eijck CH, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, Koning GA, Eggermont AM and Ten Hagen TL: Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer. Eur J Surg Oncol. 38:1058–1064. 2012. View Article : Google Scholar : PubMed/NCBI | |
Jin K, Luo G, Xiao Z, Liu Z, Liu C, Ji S, Xu J, Liu L, Long J, Ni Q and Yu X: Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des Devel Ther. 9:1247–1255. 2015. View Article : Google Scholar : PubMed/NCBI | |
Ansari D, Gustafsson A and Andersson R: Update on the management of pancreatic cancer: Surgery is not enough. World J Gastroenterol. 21:3157–3165. 2015.PubMed/NCBI | |
Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, et al: Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 26:3496–3502. 2008. View Article : Google Scholar : PubMed/NCBI | |
Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, et al: Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 26:3487–3495. 2008. View Article : Google Scholar : PubMed/NCBI | |
Cho SW, Tzeng CW, Johnston WC, Cassera MA, Newell PH, Hammill CW, Wolf RF, Aloia TA and Hansen PD: Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: Analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). HPB (Oxford). 16:350–356. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lind PA, Isaksson B, Almström M, Johnsson A, Albiin N, Byström P and Permert J: Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol. 47:413–420. 2008. View Article : Google Scholar : PubMed/NCBI | |
Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992. View Article : Google Scholar : PubMed/NCBI | |
Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, et al: The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol. 20 Suppl 3:S500–S5008. 2013. View Article : Google Scholar : PubMed/NCBI | |
Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, et al: Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg. 206:833–848. 2008. View Article : Google Scholar : PubMed/NCBI | |
Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, et al: Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol. 17:2832–2838. 2010. View Article : Google Scholar : PubMed/NCBI | |
Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V and Helton S: Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 21:1530–1537. 2014. View Article : Google Scholar : PubMed/NCBI | |
Takahashi H, Ohigashi H, Gotoh K, Marubashi S, Yamada T, Murata M, Ioka T, Uehara H, Yano M and Ishikawa O: Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 258:1040–1050. 2013. View Article : Google Scholar : PubMed/NCBI | |
Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, Kooby DA, Maithel SK, Landry J and El-Rayes BF: Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 42:1311–1315. 2013. View Article : Google Scholar : PubMed/NCBI | |
Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ and Bahary N: Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 108:236–241. 2013. View Article : Google Scholar : PubMed/NCBI | |
Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM and Lacy J: FOLFIRINOX for locally advanced and metastatic pancreatic cancer: Single institution retrospective review of efficacy and toxicity. Med Oncol. 30:3612013. View Article : Google Scholar : PubMed/NCBI | |
Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, et al: Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 13:497–501. 2012.PubMed/NCBI | |
Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, et al: A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 12:1992012. View Article : Google Scholar : PubMed/NCBI | |
Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, Rabl H, Uggowitzer M, Jilek K, Leitner G and Bauernhofer T: Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol. 52:1231–1233. 2013. View Article : Google Scholar : PubMed/NCBI | |
Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB and George B: Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: A new treatment paradigm? Oncologist. 19:266–274. 2014. View Article : Google Scholar : PubMed/NCBI | |
Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, et al: FOLFIRINOX in locally advanced pancreatic cancer: The Massachusetts General Hospital Cancer Center experience. Oncologist. 18:543–548. 2013. View Article : Google Scholar : PubMed/NCBI | |
James ES, Yao X, Cong X, Li J, Hahn C, Kaley K, Kortmansky JS, Fischbach NA, Chang BW, Salem RR, et al: Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). J Clin Oncol. 32 Suppl:e152262014. View Article : Google Scholar | |
Hazariwala R, Landry J, El-Reyes B, et al: Neoadjuvant FOLFIRINOX and radiation therapy improves resectability of pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2 Suppl 1:872013. | |
Vasile E, de Lio N, Cappelli C, et al: Phase II study of neoadjuvant chemotherapy with modified FOLFOXIRI in borderline resectable or unresectable stage III pancreatic cancer. J Clin Oncol. 15(Suppl 1): 312013. | |
Kharofa J, Kelly TR, Ritch PS, George B, Wiebe LA, Thomas JP, Christians KK, Evans DP and Erickson B: 5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer. J Clin Oncol. 30 Suppl:e146132012. | |
Lowery MA, Yu KH, Adel NG, Apollo AJ, Boyar MS, Caron P, Ilson D, Segal NH, Janjigian YY, Janjigian DR, et al: Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol. 30 Suppl:40572012. | |
Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, et al: Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 22:1153–1159. 2015. View Article : Google Scholar : PubMed/NCBI | |
Nanda RH, El-Rayes B, Maithel SK and Landry J: Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 111:1028–1034. 2015. View Article : Google Scholar : PubMed/NCBI | |
Paniccia A, Edil BH, Schulick RD, Byers JT, Meguid C, Gajdos C and McCarter MD: Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: A retrospective cohort study. Medicine (Baltimore). 93:e1982014. View Article : Google Scholar : PubMed/NCBI | |
Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD and Shridhar R: Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 54:979–985. 2015. View Article : Google Scholar : PubMed/NCBI | |
Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Aitini E and Barni S: Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD): FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: A meta-analytical review of published studies. Pancreas. 44:515–521. 2015. View Article : Google Scholar : PubMed/NCBI | |
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI | |
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 304:1073–1081. 2010. View Article : Google Scholar : PubMed/NCBI | |
Katz MH, Shi Q, Ahmad SA, Herman JM, de Marsh RW, Collisson EA, Schwartz LH, Martin RC, Conway WC, Truty M, et al: Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. J Clin Oncol. 33(Suppl): abstr 4008. 2015. | |
Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)-A Single-centre Phase 2a Study of Gemcitabine Plus Nab-paclitaxel for Borderline Unresectable Locally Advanced Pancreatic Cancer. ClinicalTrials.gov Identifier: NCT02124369. 2017. | |
Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, et al: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration. Ann Surg Oncol. 8:123–132. 2001. View Article : Google Scholar : PubMed/NCBI | |
Ishikawa O, Ohhigashi H, Teshima T, Chatani M, Inoue T, Tanaka S, Kitamura T, Wada A, Sasaki Y, Imaoka S, et al: Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol. 40:143–151. 1989. View Article : Google Scholar : PubMed/NCBI | |
Washington K, Berlin J and Branton P: Protocol for the examination of specimens from patients with carcinoma of the exocrine pancreas: Protocol applies to all epithelial tumors of the exocrine pancreas. Endocrine tumors and tumors of the ampulla of Vater are not included Northfield, IL: College of American Pathologists; 2010 | |
Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y and Yachida S: Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 258:336–346. 2013. View Article : Google Scholar : PubMed/NCBI | |
Pendurthi TK, Cooper HS, Young NA, et al: Histopathologic effects of preoperative chemoradiotheraoy on pancreatic carcinoma. Gastroenterology. 110:A1410. 1996. | |
White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS, et al: Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 12:214–221. 2005. View Article : Google Scholar : PubMed/NCBI | |
Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF and Eisenberg BL: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Analysis of histopathology and outcome. Int J Gastrointest Cancer. 34:121–128. 2003. View Article : Google Scholar : PubMed/NCBI | |
Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, Guttmann MC, Litwin S, Salazar H and Eisenberg BL: A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg. 169:71–78. 1995. View Article : Google Scholar : PubMed/NCBI | |
Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, et al: Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 29:2773–2780. 2011. View Article : Google Scholar : PubMed/NCBI | |
García-Aguilar J, de Anda E Hernandez, Sirivongs P, Lee SH, Madoff RD and Rothenberger DA: A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 46:298–304. 2003. View Article : Google Scholar : PubMed/NCBI | |
Martin ST, Heneghan HM and Winter DC: Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 99:918–928. 2012. View Article : Google Scholar : PubMed/NCBI | |
Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, et al: Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol. 11:835–844. 2010. View Article : Google Scholar : PubMed/NCBI | |
Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S and Karl R: Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 17:1159–1167. 2010. View Article : Google Scholar : PubMed/NCBI | |
Pasini F, de Manzoni G, Zanoni A, Grandinetti A, Capirci C, Pavarana M, Tomezzoli A, Rubello D and Cordiano C: Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: A phase 2 study. Cancer. 119:939–945. 2013. View Article : Google Scholar : PubMed/NCBI | |
Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA and Ajani JA: Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 104:2365–2372. 2005. View Article : Google Scholar : PubMed/NCBI | |
Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H and Goldberg M: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 23:4330–4337. 2005. View Article : Google Scholar : PubMed/NCBI | |
Vallböhmer D, Hölscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schröder W, Bollschweiler E and Hofstetter W: A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 252:744–749. 2010. View Article : Google Scholar : PubMed/NCBI | |
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 25:4414–4422. 2007. View Article : Google Scholar : PubMed/NCBI | |
Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, et al: Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: Pathologic response correlates with five-year overall survival. Breast Cancer Res Treat. 124:723–732. 2010. View Article : Google Scholar : PubMed/NCBI | |
Sherman WH, Chu K, Chabot J, Allendorf J, Schrope BA, Hecht E, Jin B, Leung D, Remotti H, Addeo G, et al: Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer. 121:673–680. 2015. View Article : Google Scholar : PubMed/NCBI | |
Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, Zureikat AH, Bahary N and Zeh HJ III: Serum CA 19–9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 21:4351–4358. 2014. View Article : Google Scholar : PubMed/NCBI | |
Rajagopalan MS, Heron DE, Wegner RE, Zeh HJ, Bahary N, Krasinskas AM, Lembersky B, Brand R, Moser AJ, Quinn AE and Burton SA: Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat Oncol. 8:2542013. View Article : Google Scholar : PubMed/NCBI | |
Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park DH, Seo DW, Lee SK, Kim MH, Kim JH, et al: Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 152:851–862. 2012. View Article : Google Scholar : PubMed/NCBI | |
Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, Balachandran A, Varadhachary GR, Pisters PW, Wang H, et al: Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 16:29–37. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN, Crane C, et al: Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: A predictor for patient outcome. Cancer. 118:3182–3190. 2012. View Article : Google Scholar : PubMed/NCBI | |
Barugola G, Partelli S, Crippa S, Capelli P, D'Onofrio M, Pederzoli P and Falconi M: Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 203:132–139. 2012. View Article : Google Scholar : PubMed/NCBI | |
Le Scodan R, Mornex F, Partensky C, Mercier C, Valette PJ, Ychou M, Bibeau F and Scoazec JY: Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma. Cancer Radiother. 15:97–105. 2011. View Article : Google Scholar : PubMed/NCBI | |
Turrini O, Ychou M, Moureau-Zabotto L, Rouanet P, Giovannini M, Moutardier V, Azria D, Delpero JR and Viret F: Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol. 36:987–92. 2010. View Article : Google Scholar : PubMed/NCBI | |
Magnin V, Moutardier V, Giovannini MH, Lelong B, Giovannini M, Viret F, Monges G, Bardou VJ, Alzieu C and Delpero JR: Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys. 55:1300–1304. 2003. View Article : Google Scholar : PubMed/NCBI | |
Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ and Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg. 135:81–88. 2000. View Article : Google Scholar : PubMed/NCBI |